Results 191 to 200 of about 19,665 (228)
Some of the next articles are maybe not open access.
Systemic Juvenile Idiopathic Arthritis
Pediatric Clinics of North America, 2018Systemic juvenile idiopathic arthritis (sJIA) is a distinctive subtype of juvenile idiopathic arthritis, characterized by fever and arthritis, often accompanied by rash, sometimes by generalized lymphadenopathy, hepatosplenomegaly, and serositis. The diagnosis requires adequate exclusion of infectious, oncologic, autoimmune, and autoinflammatory ...
Jennifer J Y Lee, Rayfel Schneider
exaly +3 more sources
Canakinumab for the treatment of active systemic juvenile idiopathic arthritis
Expert Review of Clinical Pharmacology, 2016Canakinumab, a fully human monoclonal antibody against interleukin-1β, is a relatively new medication approved for treatment of systemic juvenile idiopathic arthritis (SJIA). Here, we review data supporting use of canakinumab for patients with active SJIA, as compared to other available biologic medications.This article provides an overview of ...
Norman T Ilowite
exaly +3 more sources
Systemic Juvenile Idiopathic Arthritis: A Review
Pediatric Annals, 2012CME Educational Objectives 1. Become familiar with the clinical presentation, differential diagnosis and potential complications of systemic juvenile idiopathic arthritis. 2.
Arielle D, Hay, Norman T, Ilowite
openaire +2 more sources
Glucocorticoids in the Management of Systemic Juvenile Idiopathic Arthritis
Pediatric Drugs, 2013Glucocorticoids have been the mainstay of treatment for many years in systemic-onset juvenile idiopathic arthritis (sJIA), causing important side effects and some difficulties in the management of this disease. Until the introduction of biologic agents, oral glucocorticoids were used to control fever and other systemic features for several months or ...
G. Vannucci +7 more
openaire +4 more sources
Systemic Juvenile Idiopathic Arthritis
2019Systemic-onset juvenile idiopathic arthritis is a complex, polygenic autoinflammatory disease affecting young individuals. It is an innate immunity-driven condition characterized by chronic, multiorganic inflammatory involvement. Typical clinical features including young age at presentation, fever, neutrophilic skin lesions, synovitis, serositis ...
Ricardo A. G. Russo +1 more
openaire +1 more source
Giant Iliopsoas Bursitis in Systemic Juvenile Idiopathic Arthritis
Arthritis & Rheumatology, 2021A 4-year-old boy with systemic juvenile idiopathic arthritis (sJIA) relapsed while on tacrolimus and tocilizumab (TCZ). He presented with right groin pain and claudication. The patient had mild tenderness and restricted range of motion in his right hip joint on physical examination. Furthermore, no mass was palpable.
Asami Shimbo +4 more
openaire +2 more sources
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Expert Review of Clinical Immunology, 2012Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood, resulting in short- and long-term disability. It includes a heterogeneous group of diseases, of which systemic JIA is often resistant to treatment. IL-6 plays a significant role in systemic JIA since it is elevated in serum and correlates with disease activity ...
openaire +3 more sources
Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis
Pediatric Drugs, 2020Systemic juvenile idiopathic arthritis (sJIA) is a severe disorder now linked more to autoinflammation than to autoimmunity. Clinical and laboratory evidence support the pathogenetic role of interleukin-1 (IL-1), and blockade of this cytokine has proved to be very effective in the treatment of sJIA.
Mejbri M +3 more
openaire +3 more sources
Canakinumab for the treatment of systemic juvenile idiopathic arthritis
Expert Review of Clinical Immunology, 2014The introduction of methotrexate in the 1980s and of TNF-inhibiting agents and abatacept in the late 1990s led to a dramatic improvement in the outcomes of non-systemic categories of juvenile idiopathic arthritis. By contrast, the same treatment approaches had no strong impact on the outcome of systemic juvenile idiopathic arthritis (SJIA), and the ...
openaire +2 more sources
Treatment of non-systemic juvenile idiopathic arthritis
Nature Reviews RheumatologyIn the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly, owing to the availability of a growing number of novel, potent and relatively safe therapeutic agents and the shift of management strategies towards early achievement of disease remission.
Susan Shenoi +3 more
openaire +2 more sources